Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 16, keine Gesamtzahl für „Table“
Suchtreffer
Begriffe & Kennungen
Capecitabine Teva · 4.8 · In addition to the ADRs described in tables 4 and 5, the following ADRs with an incidence of less than 0.1% we
Eintrag öffnenCapecitabine Teva · 4.8 · In the instance of exposure to crushed or cut capecitabine tablets, the following adverse drug reactions have
Eintrag öffnenCapecitabine Teva · 4.8 · Table 4 Summary of related ADRs reported in patients treated with capecitabine monotherapy
Eintrag öffnenCapecitabine Teva · 4.8 · Table 5 Summary of related ADRs reported in patients treated with capecitabine in combination treatment in add
Eintrag öffnenCarboxypeptidase U
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Summary of the safety profile The table includes adverse reactions that were presented during treatment with t
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · The following table includes adverse reactions of carmustine listed by MedDRA system organ class and frequency
Eintrag öffnenCarvykti · 4.8 · Table 4: Adverse reaction in patients with multiple myeloma treated with CARVYKTI Incidence (%) All grade ≥ Sy
Eintrag öffnenCarvykti · 4.8 · Table 5 lists the incidences of Grade 3 or Grade 4 cytopenias occurring after dosing not resolved to Grade 2 o
Eintrag öffnenCarvykti · 4.8 · Table 5: Incidences of prolonged and recurrent cytopenias following treatment with CARVYKTI (N=396) Initial Gr
Eintrag öffnenCarvykti · 4.8 · Tabulated list of adverse reactions Table 4 summarises the adverse reactions that occurred in patients receivi
Eintrag öffnenCasgevy · 4.8 · Table 1: Adverse reactions attributed to mobilisation/apheresis in patients with TDT receiving G-CSF and pleri
Eintrag öffnenCasgevy · 4.8 · Table 2: Adverse reactions attributed to mobilisation/apheresis in patients with SCD receiving plerixafor (N=5
Eintrag öffnenCasgevy · 4.8 · Table 3: Adverse reactions attributed to myeloablative conditioning with busulfan in patients with TDT and SCD
Eintrag öffnenCasgevy · 4.8 · Table 4: Adverse reactions attributed to Casgevy in patients with TDT and SCD (N=97) * System organ class (SOC
Eintrag öffnenCasgevy · 4.8 · Tables 1, 2, 3, and 4 are lists of adverse reactions attributed to mobilisation/apheresis with G-CSF and pleri
Eintrag öffnenCatiolanze · 4.8 · The table below describes adverse reactions for preserved latanoprost eye drops, solution from clinical trials
Eintrag öffnenCavoley · 4.8 · Table 1: List of adverse reactions
Eintrag öffnenCavoley · 4.8 · The data in the table below describe adverse reactions reported from clinical trials and spontaneous reporting
Eintrag öffnenCegfila (previously Pegfilgrastim Mundipharma) · 4.8 · Tabulated list of adverse reactions The data in the table below describe adverse reactions reported from clini
Eintrag öffnen